Natural products and supplements for geriatric depression and cognitive disorders: An evaluation of the research

Current Psychiatry Reports

Volumn 16, Issue 8, 2014, Pages

  Varteresian, Taya ^b,c   Lavretsky, Helen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Caprylidene; Coconut oil; Cognition; Cognitive disorder; Complementary and alternative medicine; Cyanocobalamin; Dementia; Folic acid; Geriatric; Ginkgo biloba; Huperzine; Integrative medicine; Mood disorders; Natural products; Omega 3 fatty acids; Pyridoxine; SAMe; St. John's Wort; Supplements; Vitamin B; Vitamin D

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; VITAMIN;

ALTERNATIVE MEDICINE; COGNITION DISORDERS; DEPRESSIVE DISORDER; DIET SUPPLEMENTATION; HUMAN; PHYTOTHERAPY; PROCEDURES;

ANTIDEPRESSIVE AGENTS; COGNITION DISORDERS; COMPLEMENTARY THERAPIES; DEPRESSIVE DISORDER; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; VITAMINS;

EID: 84901882104     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0456-x     Document Type: Review

References (87)

1. Lavretsky H et al. Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders. Aging Health. 2009;5(1):61-78.
2. Lange H et al. Folate therapy in-stent restenosis after coronary stenting. N Engl J Med. 2004;350:2673-81. (Pubitemid 38788002)
3. Mozaffari-Khosravi H. The effect of 2 different single injections of high dose of vitamin D on improving the depression in depressed patients with vitamin D deficiency. J Clin Psychopharmacol. 2012;33(3):378-84.
4. Michaelsson K et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841-8.
5. NCCAM-NIH Website. What is Complementary and Alternative Medicine? http://nccam.nih.gov/health/whatiscam/. (National Center for Complementary and Alternative Medicine - National Institutes of Health, 2010).
6. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States. Natl Health Stat Rep. 2007;2008:1-23.
7. US Food and Drug Administration. Orphan Drug Act (21 U.S.C. 360ee (b) (3)). Retrieved April 20, 2014, from http://www.fda.gov/food/guidanceregulation/ guidancedocumentsregulatoryinformation/medicalfoods/default.htm (1988).
8. Bertrand PC, O'Kusky JR, Innis SM. Maternal dietary (n-3) fatty acid deficiency alters neurogenesis in the embryonic rat brain. J Nutr. 2006;136(6):1570-5. (Pubitemid 43765364)
9. Birch E et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol. 2000;42:174-81. (Pubitemid 30145332)
10. Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351:1213.
11. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamaki H. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry. 2001;58:512-3. (Pubitemid 32411335)
12. Timonen M, Horrobin D, Jokelainen J, Laitinen J, Herva A, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord. 2004;82:447-52. (Pubitemid 39536178)
13. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr. 2010;91:757-70.
14. •• Sublette ME, Steven PE, Gleant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry. 2011;72:1577-84. Summary of dosing and proportion of omega-3 fatty acids and depression in general adult population.
15. Rondanelli M, Giacosa A, Opizzi A, et al. Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life. J Nutr Health Aging. 2011;15:37-44.
16. Giltay E, Geleijinse JM, Dromhout D. Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr. 2011;94:1442-50.
17. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999;56:407-12. (Pubitemid 29215428)
18. •• Sarris J, Dischoulon D, Schweitzer I. Omega-3 for bipolar disorder : meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2012;73:81-6. Summary of omega-3 fatty acids and bipolar disorder in general adult population.
19. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol. 2009;5:140-52.
20. Schaefer EJ et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol. 2006;63(11):1545-50. (Pubitemid 44748796)
21. Barberger-Gateau P et al. Dietary patterns and risk of dementia. Neurology. 2007;69:1921-30.
22. •• Mazereeuw G, et al. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. Neurobiol. Aging. 2012;1482.e17-1482. e29. Omega-3 fatty acids can be helpful in mild cognitive impairment but no AD or normal cognition.
23. •• Sydenham E, et al. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database Syst Rev. 2012. Summary of 3 well -designed studies showing no support for omega-3 fatty acids preventing the development of AD
24. Trofimiuk E, Walesiuk A, Braszko JJ. St. John's wort (Hypericum perforatum) diminishes cognitive impairment caused by chronic restraint stress in rats. Pharmacol Res. 2004;51:239-46. (Pubitemid 40127216)
25. Hammerness P et al. St. John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003;44(4):271-82. (Pubitemid 36750533)
26. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst. Rev. 2008;CD000448.
27. Kasper S, Gastpar M, Moller HJ, Muller WE, Volz HP, Dienel A, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25:204-13.
28. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. J Am Med Assoc. 2002;287:1807-14.
29. Shelton RC. St John's wort (Hypericum perforatum) in major depression. J Clin Psychiatry. 2009;70 Suppl 5:23-7.
30. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285:1978-86. (Pubitemid 32366950)
31. Sarris J, Fava M, Schweitzer I, Mischoulon D. St. John's wort (hypericum perforatum) verses sertraline and placebo in major depressive disorder : continuation data from a 26-week RCT. Pharmacopsychiatry. 2012;45(7):275-8.
32. Harrer G, Schmidt U, Kuhn U, Biller A. Comparison of equivalence between the St. John's wort extract LoHyp-57 and fluoxetine. Arzneimittelforschung. 1999;49:289-96. (Pubitemid 29198106)
33. Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H. St. John's wort extract L160 for the treatment of depression with atypical features-a double-blind randomized, and placebo-controlled trial. J Psychiatr Res. 2001;44:760-7.
34. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69:1777-98.
35. Kashiwaya Y et al. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. PNAS. 2000;97(5):5440-4. (Pubitemid 30313737)
36. Izzo AA et al. Interactions between herbal medicines and prescribed drugs an updated systematic reviews. Drugs. 2009;69(13):1888-98.
37. •• Thaipisuttikul P, Galvin J. Use of medical foods and nutritional approaches in treatment of Alzheimer's disease. Clin Pract. 2012;9(2):199-209. Review of 3 popular medical foods for dementia.
38. •• Varteresian T et al. The use of natural products and supplements in late-life mood and cognitive disorders. FOCUS. 2013;11(1):15-21. Previous review of Natural products by current authors.
39. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S-61.
40. Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J Clin Psychiatry. 2009;70 Suppl 5:18-22.
41. Paul RT, McDonnell AP, Kelly CB. Folic acid: neurochemistry, metabolism and relationship to depression. Hum Psychopharmacol. 2004;19:477-88. (Pubitemid 39378270)
42. Bottiglieri T et al. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 1990;53:1096-8.
43. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
44. Alpert JE et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder. J Clin Psychopharmacol. 2004;24(6):661-4.
45. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010;167:942-8.
46. DiRocco A et al. S-adenosyl-methionine improves mdepression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord. 2000;15(6):1225-9.
47. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002;76:1158S-61.
48. Carney MW, Chary TK, Bottiglieri T, Reynolds EH, Toone BK. Switch mechanism in affective illness and oral Sadenosylmethionine (SAM). Br J Psychiatry J Ment Sci. 1987;150:724-5. (Pubitemid 17061248)
49. Chitiva H, Audivert F, Alvarez C. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine. J Nerv Ment Dis. 2012;200:99-101.
50. Fontanari D, Palma C, Giorgetti G, Violante F, Voltolina M. Effects of S-adenosyl-L-methionin on cognitive and vigilance functions in the elderly. Curr Ther Res. 1994;55:682-8.
51. • Levkovitz Y, Alpert J, Brintz C, Mischoulon D, Papakostas G. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord. 2011;136:1174-8. RCT showing SAMe augmentation of SSRI benefiting cognitive symptoms in depression.
52. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300:2253-62.
53. Kohler S, Funk P, Kieser M. Influence of 7-day treatment with ginkgo biloba special extract Egb 761 on bleeding time and coagulation : a randomized, placebo-controlled, double-blind study in healthy volunteers. Blood Coagul Fibrinolysis. 2004;15:303-9. (Pubitemid 38757057)
54. •• Vellas B et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 2012;11:851-9. Well designed study showing lack of preventatie effect of Ginkgo Biloba on the development of dementia.
55. Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009; 2663-2670.
56. Amieva H et al. Ginkgo biloba extract and long-term cognitive decline : a 20-year follow-up population based study. PLoS ONE. 2013;8(1):e52755.
57. Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of a once daily formulation of ginkgo biloba extract EGb 761 in Alzheimer's Disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012;45:41-6. RCT showing ginkgo biloba being effective for multiple types of dementia.
58. Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157:295-300. (Pubitemid 47356252)
59. Sierpina VS et al. Ginkgo biloba. Am Fam Physician. 2003;68(5):923-6. (Pubitemid 37093220)
60. • Zhi-Qiang X, Xiao-Min L, Juan W, Yuan-Feng Z, Chun-Xia Z, Xiao-Jiang J. Treatment with huperzine A improves cognition in vascular dementia patients. Cell Biochem Biophys. 2012;62:55-8. Study from China showing Huperzine being effective for vascular dementia.
61. •• Rafii MS et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76:1389-94. Study from U.S. showing only high dosage huperzine being effective for Alzheimer's disease.
62. Beydoun M, Shroff M, Beydoun H, Zonderman A. Serum folate, vitamin B-12, and homocysteine and their associations with depressive symptoms among US adults. Psychosom Med. 2010;72:862-73.
63. Forti P, Rietti E, Pisacane N, Olivelli V, Dalmonte E, Mecocci P, et al. Blood homocysteine and risk of depression in the elderly. Arch Gerontol Geriatr. 2010;51:21-5.
64. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan A, Breteler M. Vitamin B12, folate, and homocysteine in depression : the Rotterdam Study. Am J Psychiatr. 2002;159:2099-101. (Pubitemid 35423873)
65. Walker J et al. Mental health literacy, folic acid and vitamin B12 and physical activity for the prevention of depression in older adults : randomized controlled trial. Br J Psychiatry. 2010;197:45-54.
66. Almeida O, Marsh K, Alfonso H, Flicker L, Davis T, Hankey G. B-vitamins reduce the long-term risk of depression after stroke : the VITATOPS-DEP trial. Ann Neurol. 2010;68:503-10.
67. •• Papakostas GI et al. L-methyfolate as adjunctive therapy for SSRI-resistant major depression : results of two randomized, double blind, paralleel-sequential trials. Am J Psychiatry. 2012;169(12):1267-74. Well -designed study showing benefit of l-methyfolate augmentation of antidepressant in general adult population.
68. Resler G, Lavie R, Campos J, Mata S, Urbina M, Garcia A, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12 and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15:145-52.
69. Abou-Saleh M, Coppen A. Folic acid and the treatment of depression. J Psychosom Res. 2006;61:285-7. (Pubitemid 44376393)
70. Seeley WW, Miller BL. Chapter 371. Dementia. In: Longo DL, Fauci, AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's principles of internal medicine, 18e. Retrieved September 17, 2012 from http://www. accessmedicine.com/content.aspx?aID=9146233 (2012).
71. Tangney CC et al. Vitamin B12, cognition, and brain MRI measures. Neurology. 2011;77:1276-82.
72. Aisen P, Schneider L, Sano M, Fiaz-Arrastia R, van-Dyck C, Weiner M, et al. High dose B vitamin supplementation and cognitive decline in Alzheimer Disease. JAMA. 2008;300:1774-83.
73. Kwok T et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30:297-302.
74. • Walker J et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms-the Beyond Aging Project : a randomized controlled trial. Am J Clin Nutr. 2012;95:194-203. In older adults with depressive symptoms but without dementia showed vitamin B12 supplementation can improve attention and delayed recall.
75. • Mursu J, Robien K, Harnack L, Park K, Jacobs D. Dietary supplements and mortality rate in older women. Arch Intern Med. 2011;171:1625-33. Epidemioliogical study showing some risk of supplements in increasing mortality in older women.
76. • Tariq MM et al. Vitamin D : a potential role in reducing suicide risk. Int J Adolesc Med Health. 2011;23(3):157-65. Correlation between vitamin D deficiency and increased risk for suicide in general adult popultation.
77. Dumville JC et al. Can vitamin D supplementation prevent winter-time blues ? a randomized trial among older women. J Nutr Health Aging. 2006;10(2):151-3.
78. Chan A, et al. Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: a 1-year, open label pilot study with a 16-month caregiver extension. Am J Alzheimers Dis Other Dement. 2009;571-585.
79. • Bertone-Johnson ER et al. Vitamin D supplementation and depression in the Women's Health Initiative Calcium and Vitamin D Trial. Am J Epidemiol. 2011;176(1):1-13. Low dosage vitamin D supplementation did not improve depression in older females suffering from depression.
80. Jorde R et al. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects : randomized double blind trial. J Intern Med. 2008;264:599-609.
81. Henderson ST et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease : a randomized, double-blind placebo-controlled multicenter trial. Nutr Metab. 2009;6:31.
82. • Doty L. Coconut oil for Alzheimer's disease. Clin Pract. 2012;1(2):12-7. Review demonstrating how coconut oil is not effective for Alzheimer's disease.
83. Stoll AL, Damico KE, Daly BP, Severus WE, Marangell LB. Methodological considerations in clinical studies of omega 3 fatty acids in major depression and bipolar disorder. World Rev Nutr Diet. 2001;88:58-67. (Pubitemid 33210315)
84. Michaelsson K, Baron J, Snellman G, Gedborg R, Byberg L, Sundstrom J, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr. 2010;92:841-48.
85. •• Qureshi NA et al. Mood disorders and complementary and alternative medicine: a literature review. Neuropsychiatr Dis Treat. 2013;9:639-58. Extensive review of CAM for adult mood disorders.
86. Kaustubh JG, Faubion MD. Mania and psychosis associated with St. John's wort and ginseng. Psychiatry. 2005;56-61.
87. Borrelli F, Izzo AA. Herb-drug interactions with St. John's wort (Hypericum perforatum) an update on clinical observations. AAPS J. 2009;11:710-27.